首页 > 市场调查报告书 > 製药

生物製剂

市场调查报告书

商品编码

1684413

重组蛋白治疗 CDMO 市场，按类型、按适应症、按来源、按国家和地区 - 2025 年至 2032 年的行业分析、市场规模、市场份额和预测

Recombinant Protein Therapeutics CDMO Market, By Type, By Indication, By Source, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

出版日期: 2025年03月04日 | 出版商:

AnalystView Market Insights | 英文 316 Pages | 商品交期: 2-3个工作天内

价格

简介目录

报告重点

2024 年重组蛋白治疗 CDMO 市场规模价值为 209.2032 亿美元，2025 年至 2032 年的复合年增长率为 13.98%。

重组蛋白治疗 CDMO 市场 - 市场动态

生物製剂需求的不断增长和生物加工技术的发展预计将推动市场需求

重组蛋白治疗 CDMO 市场的成长受到生物製剂需求不断增长的推动，再加上生物製剂生产的复杂性，促使製药和生物技术公司依赖专门的 CDMO。生物相似药是原始生物製剂的经济高效版本，正在获得市场认可，进一步推动重组蛋白生产对 CDMO 服务的需求，促进市场成长。一次性生物反应器、连续製造和高产量表达系统（如CHO和HEK293细胞）提高了蛋白质生产的效率。上游和下游加工的创新提高了蛋白质的产量，降低了整体生产成本和时间。

个人化医疗和精准治疗的兴起增加了对客製化重组蛋白的需求。基于重组蛋白的细胞和基因疗法正在扩大 CDMO 在先进生物製剂中的作用。此外，肿瘤学、罕见疾病和再生医学领域的新兴应用正在推动市场成长。亚太地区，特别是中国、印度和韩国，由于成本较低和政府支持政策，正在成为生物製药製造中心。因此，许多 CDMO 正在这些地区建立设施，以满足对廉价生物製剂日益增长的需求。

重组蛋白治疗 CDMO 市场 - 关键见解

根据我们的研究分析师的分析，预测期内（2025-2032 年），全球市场预计年复合成长率约为 13.98%

根据类型细分，由于传染病患者病率高，干扰素部分预计将在 2024 年占据最大市场份额。

根据适应症细分，其他细分市场将成为 2024 年领先的适应症细分市场，这是因为高盛行率疾病导致对蛋白质疗法的需求很高。

根据来源细分，哺乳动物系统部分是 2024 年领先的来源部分，因为它们在人类糖蛋白中有广泛的应用。

按地区划分，得益于政府的支持政策和运输业的发展，北美将成为 2024 年的主要收入来源。

重组蛋白治疗 CDMO 市场-細項分析：

全球重组蛋白治疗 CDMO 市场根据类型、适应症、来源和地区进行细分。

市场依类型分为五大类：生长激素、干扰素、疫苗、免疫刺激剂和其他。干扰素领域占据市场主导地位。传染病发病率的不断上升是刺激该领域成长的主要原因。

根据适应症，市场分为六类：肿瘤学、传染病、免疫系统疾病、代谢疾病、血液疾病和其他。预计其他部分将占据最大份额。预计预测期内代谢紊乱部分将以最快的速度成长。

根据来源，市场分为三类：哺乳动物系统、微生物系统和其他。哺乳动物系统部分占据来源部分的最大份额。生物药物、基因工程等应用的不断增加预计将促进市场成长。

重组蛋白治疗 CDMO 市场 - 地理洞察

在全球范围内，重组蛋白治疗CDMO市场广泛分布于北美、拉丁美洲、欧洲、亚太地区以及中东和非洲地区。北美在重组蛋白治疗 CDMO 市场中占有突出地位。美国已成为重组蛋白药物生产领域的全球领导者。该国强大的研发基础设施和发达的生物製药製造能力促进了市场成长。亚太地区的重组蛋白治疗 CDMO 市场可望大幅成长。造成这种情况的因素包括慢性病发病率上升、医疗保健支出增加以及生物技术投资增加，这些都提供了成长机会。中东和非洲的重组蛋白治疗 CDMO 市场正在经历中等成长。

重组蛋白治疗 CDMO 市场-竞争格局：

重组蛋白治疗 CDMO 市场竞争激烈，几家主要参与者都在努力增强其服务产品并扩大其市场占有率。市场参与者为生物製药（包括重组蛋白）的开发和製造提供全面的服务。一些公司专门从事治疗性蛋白质的开发和製造，提供从细胞株开发到商业生产的服务。

介绍
- 按地区分類的细分市场占有率分析
北美洲
- 概述
- 北美重组蛋白治疗 CDMO 主要製造商
- 北美市场规模及预测（按国家/地区）
- 北美市场规模和预测（按类型）
- 北美市场规模及预测（依适应症划分）
- 北美市场规模与预测，依来源划分
- 我们
- 加拿大
欧洲
- 概述
- 欧洲重组蛋白治疗 CDMO 主要製造商
- 欧洲市场规模及预测（按国家）
- 欧洲市场规模与预测（按类型）
- 欧洲市场规模及预测（按适应症）
- 欧洲市场规模与预测，按来源
- 德国
- 英国
- 法国
- 义大利
- 西班牙
- 荷兰
- 瑞典
- 俄罗斯
- 波兰
- 欧洲其他地区
亚太地区 (APAC)
- 概述
- 亚太地区重组蛋白治疗 CDMO 主要製造商
- 亚太地区市场规模及预测（依国家/地区划分）
- 亚太地区市场规模及预测（按类型）
- 亚太地区市场规模及预测（依适应症划分）
- 亚太地区市场规模及预测（依来源划分）
- 中国
- 印度
- 日本
- 韩国
- 澳洲
- 印尼
- 泰国
- 菲律宾
- 亚太地区其他地区
拉丁美洲 (LATAM)
- 概述
- 拉丁美洲重组蛋白治疗 CDMO 主要製造商
- 拉丁美洲市场规模及预测（按国家/地区）
- 拉丁美洲市场规模及预测（按类型）
- 拉丁美洲市场规模及预测（依适应症划分）
- 拉丁美洲市场规模及预测（按来源）
- 巴西
- 墨西哥
- 阿根廷
- 哥伦比亚
- 拉丁美洲其他地区
中东和非洲 (MEA)
- 概述
- 中东和非洲重组蛋白治疗 CDMO 主要製造商
- MEA 市场规模及预测（依国家/地区划分）
- MEA 市场规模和预测（按类型）
- MEA 市场规模及预测（依适应症划分）
- MEA 市场规模和预测，按来源
- 沙乌地阿拉伯
- 阿联酋
- 以色列
- 土耳其
- 阿尔及利亚
- 埃及
- MEA 其他地区

第 11 章：主要供应商分析-重组蛋白治疗 CDMO 产业

竞争仪錶板
- Competitive Benchmarking
- Competitive Positioning
公司简介
- Richter-Helm BioLogics
- Lonza
- Catalent, Inc
- FUJIFILM Diosynth Biotechnologies
- WuXi Biologics
- Curia Global, Inc.
- Batavia Biosciences BV
- AGC Biologics
- Boehringer Ingelheim BioXcellence
- Repligen Corporation
- Therapure BioPharma Inc.
- Cytovance Biologics
- KBI Biopharma
- Abzena
- Patheon
- Others

第 12 章：360 度分析师视角

第 13 章：附录

研究方法
参考
缩写
免责声明
联络我们

简介目录

Product Code: ANV4798

REPORT HIGHLIGHT

Recombinant protein therapeutics CDMO Market size was valued at USD 20,920.32 Million in 2024, expanding to a CAGR of 13.98% from 2025 to 2032.

Recombinant protein therapeutics CDMO is specialized in recombinant protein therapeutics that provides services to biotech and pharmaceutical companies for the development, production, and scaling of protein-based drugs. These companies help in the end-to-end process, including cell line development, upstream and downstream processing, analytical testing, regulatory compliance, and large-scale manufacturing.

Recombinant protein therapeutics CDMO Market- Market Dynamics

Increasing demand for biologics and development in bioprocessing technologies are expected to propel market demand

The recombinant protein therapeutics CDMO market growth is driven by increasing demand for biologics, combined with the complexity of their production, has driven pharmaceutical and biotech companies to rely on specialized CDMOs. Biosimilars, which are cost-effective versions of original biologics, are gaining market acceptance, further driving the demand for CDMO services in recombinant protein production, boosting market growth. Single-use bioreactors, continuous manufacturing, and high-yield expression systems (such as CHO and HEK293 cells) have enhanced the efficiency of protein production. Innovations in upstream and downstream processing have improved protein yields, reducing overall production costs and timelines.

The rise of personalized medicine and precision therapeutics has increased demand for customized recombinant proteins. Recombinant protein-based cell and gene therapies are expanding the role of CDMOs in advanced biologics. Further, emerging applications in oncology, rare diseases, and regenerative medicine are fueling market growth. Asia-Pacific, particularly China, India, and South Korea, is becoming a hub for biopharmaceutical manufacturing due to lower costs and supportive government policies. Thus, many CDMOs are setting up facilities in these regions to cater to the growing demand for affordable biologics.

Recombinant protein therapeutics CDMO Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 13.98% over the forecast period (2025-2032)

Based on Type segmentation, the interferons segment was predicted to show maximum market share in the year 2024, due to high prevalence of infectious diseases.

Based on Indication segmentation, the others segment was the leading Indication segment in 2024, due to the high demand for protein therapeutics due to high prevalence disorders.

Based on Source segmentation, the mammalian systems segment was the leading Source segment in 2024, due to their high applications in human glycoproteins.

On the basis of region, Norh America was the leading revenue generator in 2024, owing to supportive government policies & development in transportation sector.

Recombinant protein therapeutics CDMO Market- Segmentation Analysis:

The Global Recombinant protein therapeutics CDMO Market is segmented on the basis of Type, Indication, Source, and Region.

The market is divided into five categories based on Type: growth hormones, interferons, vaccines, immunostimulant agents, and others. The interferons segment dominates the market. The increasing prevalence of infectious disorders is mainly spurring segment growth.

The market is divided into six categories based on Indication: oncology, infectious diseases, immunological disorders, metabolic disorders, hematological disorders, and others. The others segment is expected to hold the largest share. The metabolic disorders segment is expected to grow at the fastest rate over the forecast period.

The market is divided into three categories based on Source: mammalian system, microbial systems, and others. The mammalian systems segment holds the largest share of the source segment. The increasing applications biological drugs, genetical engineering are anticipated to bolster market growth.

Recombinant protein therapeutics CDMO Market- Geographical Insights

Across the world, the Recombinant protein therapeutics CDMO market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America holds a prominent position in the recombinant protein therapeutics CDMO market. The United States has established itself as a global leader in the production of recombinant protein drugs. The country's strong research and development infrastructure and well-developed biopharmaceutical manufacturing capabilities contribute to market growth. The Asia-Pacific region is poised for significant growth in the recombinant protein therapeutics CDMO market. Factors contributing to this include a rising prevalence of chronic diseases, increased healthcare expenditures, and growing investments in biotechnology are offering growth opportunities. The Middle East and Africa are experiencing moderate growth in the recombinant protein therapeutics CDMO market.

Recombinant protein therapeutics CDMO Market- Competitive Landscape:

The recombinant protein therapeutics CDMO market is characterized by intense competition, with several key players striving to enhance their service offerings and expand their market presence. market participants offer a comprehensive range of services for the development and manufacture of biopharmaceuticals, including recombinant proteins. Some of the companies specialize in the development and manufacturing of therapeutic proteins, providing services from cell line development to commercial production.

Recent Developments:

In 2024, Novo Holdings announced a USD 16.5 billion acquisition of Catalent, planning to expand production capabilities for its successful weight-loss drugs.

In June 2023, Richter-Helm BioLogics announced the plan for the development of a production site in Bovenau, Europe.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET KEY PLAYERS

Richter-Helm BioLogics
Lonza
Catalent, Inc
FUJIFILM Diosynth Biotechnologies
WuXi Biologics
Curia Global, Inc.
Batavia Biosciences B.V.
AGC Biologics
Boehringer Ingelheim BioXcellence
Repligen Corporation
Therapure BioPharma Inc.
Cytovance Biologics
KBI Biopharma
Abzena
Patheon
Others

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY TYPE- MARKET ANALYSIS, 2019-2032

Growth hormones
Interferons
Vaccines
Immunostimulant agents
Others

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY INDICATION- MARKET ANALYSIS, 2019-2032

Oncology
Infectious Diseases
Immunological disorders
Metabolic disorders
Hematological disorders
Others

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY SOURCE- MARKET ANALYSIS, 2019-2032

Mammalian system
Microbial systems
Others

GLOBAL RECOMBINANT PROTEIN THERAPEUTICS CDMO MARKET, BY REGION- MARKET ANALYSIS, 2019-2032

North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

1. Recombinant Protein Therapeutics CDMO Market Overview

1.1. Study Scope
1.2. Market Estimation Years

2. Executive Summary

2.1. Market Snippet
- 2.1.1. Recombinant Protein Therapeutics CDMO Market Snippet by Type
- 2.1.2. Recombinant Protein Therapeutics CDMO Market Snippet by Indication
- 2.1.3. Recombinant Protein Therapeutics CDMO Market Snippet by Source
- 2.1.4. Recombinant Protein Therapeutics CDMO Market Snippet by Country
- 2.1.5. Recombinant Protein Therapeutics CDMO Market Snippet by Region
2.2. Competitive Insights

3. Recombinant Protein Therapeutics CDMO Key Market Trends

3.1. Recombinant Protein Therapeutics CDMO Market Drivers
- 3.1.1. Impact Analysis of Market Drivers
3.2. Recombinant Protein Therapeutics CDMO Market Restraints
- 3.2.1. Impact Analysis of Market Restraints
3.3. Recombinant Protein Therapeutics CDMO Market Opportunities
3.4. Recombinant Protein Therapeutics CDMO Market Future Trends

4. Recombinant Protein Therapeutics CDMO Industry Study

4.1. PEST Analysis
4.2. Porter's Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis

5. Recombinant Protein Therapeutics CDMO Market: Impact of Escalating Geopolitical Tensions

5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts

6. Recombinant Protein Therapeutics CDMO Market Landscape

6.1. Recombinant Protein Therapeutics CDMO Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
- 6.2.1. Established Players' Analysis
- 6.2.2. Emerging Players' Analysis

7. Recombinant Protein Therapeutics CDMO Market - By Type

7.1. Overview
- 7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
- 7.1.2. Growth hormones
- 7.1.3. Interferons
- 7.1.4. Vaccines
- 7.1.5. Immunostimulant agents
- 7.1.6. Others

8. Recombinant Protein Therapeutics CDMO Market - By Indication

8.1. Overview
- 8.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
- 8.1.2. Oncology
- 8.1.3. Infectious Diseases
- 8.1.4. Immunological disorders
- 8.1.5. Metabolic disorders
- 8.1.6. Hematological disorders
- 8.1.7. Others

9. Recombinant Protein Therapeutics CDMO Market - By Source

9.1. Overview
- 9.1.1. Segment Share Analysis, By Source, 2024 & 2032 (%)
- 9.1.2. Mammalian system
- 9.1.3. Microbial systems
- 9.1.4. Others

10. Recombinant Protein Therapeutics CDMO Market- By Geography

10.1. Introduction
- 10.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
10.2. North America
- 10.2.1. Overview
- 10.2.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in North America
- 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.2.5. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.2.6. North America Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.2.7. U.S.
  - 10.2.7.1. Overview
  - 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.7.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.2.7.4. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.2.7.5. U.S. Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.2.8. Canada
  - 10.2.8.1. Overview
  - 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.2.8.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.2.8.4. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.2.8.5. Canada Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.3. Europe
- 10.3.1. Overview
- 10.3.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in Europe
- 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.3.5. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.3.6. Europe Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.3.7. Germany
  - 10.3.7.1. Overview
  - 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.7.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.7.4. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.7.5. Germany Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.3.8. UK
  - 10.3.8.1. Overview
  - 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.8.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.8.4. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.8.5. UK Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.3.9. France
  - 10.3.9.1. Overview
  - 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.9.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.9.4. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.9.5. France Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.3.10. Italy
  - 10.3.10.1. Overview
  - 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.10.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.10.4. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.10.5. Italy Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.3.11. Spain
  - 10.3.11.1. Overview
  - 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.11.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.11.4. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.11.5. Spain Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.3.12. The Netherlands
  - 10.3.12.1. Overview
  - 10.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.12.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.12.4. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.12.5. The Netherlands Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.3.13. Sweden
  - 10.3.13.1. Overview
  - 10.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.13.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.13.4. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.13.5. Sweden Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.3.14. Russia
  - 10.3.14.1. Overview
  - 10.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.14.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.14.4. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.14.5. Russia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.3.15. Poland
  - 10.3.15.1. Overview
  - 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.15.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.15.4. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.15.5. Poland Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.3.16. Rest of Europe
  - 10.3.16.1. Overview
  - 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.3.16.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.3.16.4. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.3.16.5. Rest of the Europe Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.4. Asia Pacific (APAC)
- 10.4.1. Overview
- 10.4.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in Asia Pacific
- 10.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.4.5. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.4.6. APAC Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.4.7. China
  - 10.4.7.1. Overview
  - 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.7.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.7.4. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.7.5. China Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.4.8. India
  - 10.4.8.1. Overview
  - 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.8.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.8.4. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.8.5. India Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.4.9. Japan
  - 10.4.9.1. Overview
  - 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.9.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.9.4. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.9.5. Japan Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.4.10. South Korea
  - 10.4.10.1. Overview
  - 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.10.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.10.4. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.10.5. South Korea Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.4.11. Australia
  - 10.4.11.1. Overview
  - 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.11.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.11.4. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.11.5. Australia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.4.12. Indonesia
  - 10.4.12.1. Overview
  - 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.12.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.12.4. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.12.5. Indonesia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.4.13. Thailand
  - 10.4.13.1. Overview
  - 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.13.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.13.4. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.13.5. Thailand Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.4.14. Philippines
  - 10.4.14.1. Overview
  - 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.14.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.14.4. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.14.5. Philippines Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.4.15. Rest of APAC
  - 10.4.15.1. Overview
  - 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.4.15.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.4.15.4. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.4.15.5. Rest of APAC Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.5. Latin America (LATAM)
- 10.5.1. Overview
- 10.5.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in Latin America
- 10.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.5.5. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.5.6. LATAM Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.5.7. Brazil
  - 10.5.7.1. Overview
  - 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.7.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.7.4. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.7.5. Brazil Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.5.8. Mexico
  - 10.5.8.1. Overview
  - 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.8.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.8.4. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.8.5. Mexico Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.5.9. Argentina
  - 10.5.9.1. Overview
  - 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.9.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.9.4. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.9.5. Argentina Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.5.10. Colombia
  - 10.5.10.1. Overview
  - 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.10.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.10.4. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.10.5. Colombia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.5.11. Rest of LATAM
  - 10.5.11.1. Overview
  - 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.5.11.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.5.11.4. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.5.11.5. Rest of LATAM Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
10.6. Middle East and Africa (MEA)
- 10.6.1. Overview
- 10.6.2. Recombinant Protein Therapeutics CDMO Key Manufacturers in Middle East and Africa
- 10.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
- 10.6.4. MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
- 10.6.5. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
- 10.6.6. MEA Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.6.7. Saudi Arabia
  - 10.6.7.1. Overview
  - 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.7.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.7.4. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.7.5. Saudi Arabia Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.6.8. UAE
  - 10.6.8.1. Overview
  - 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.8.3. UAE Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.8.4. UAE Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.8.5. UAE Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.6.9. Israel
  - 10.6.9.1. Overview
  - 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.9.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.9.4. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.9.5. Israel Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.6.10. Turkey
  - 10.6.10.1. Overview
  - 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.10.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.10.4. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.10.5. Turkey Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.6.11. Algeria
  - 10.6.11.1. Overview
  - 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.11.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.11.4. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.11.5. Algeria Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.6.12. Egypt
  - 10.6.12.1. Overview
  - 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.12.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.12.4. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.12.5. Egypt Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)
- 10.6.13. Rest of MEA
  - 10.6.13.1. Overview
  - 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
  - 10.6.13.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
  - 10.6.13.4. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  - 10.6.13.5. Rest of MEA Market Size and Forecast, By Source, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Recombinant Protein Therapeutics CDMO Industry

11.1. Competitive Dashboard
- 11.1.1. Competitive Benchmarking
- 11.1.2. Competitive Positioning
11.2. Company Profiles
- 11.2.1. Richter-Helm BioLogics
- 11.2.2. Lonza
- 11.2.3. Catalent, Inc
- 11.2.4. FUJIFILM Diosynth Biotechnologies
- 11.2.5. WuXi Biologics
- 11.2.6. Curia Global, Inc.
- 11.2.7. Batavia Biosciences B.V.
- 11.2.8. AGC Biologics
- 11.2.9. Boehringer Ingelheim BioXcellence
- 11.2.10. Repligen Corporation
- 11.2.11. Therapure BioPharma Inc.
- 11.2.12. Cytovance Biologics
- 11.2.13. KBI Biopharma
- 11.2.14. Abzena
- 11.2.15. Patheon
- 11.2.16. Others

12. 360 Degree AnalystView

13. Appendix

13.1. Research Methodology
13.2. References
13.3. Abbreviations
13.4. Disclaimer
13.5. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格